- Home
- TLN vs GMAB Comparison
TLN vs GMAB Comparison
Compare TLN & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLN
- GMAB
- Stock Information
- Founded
- TLN 2015
- GMAB 1999
- Country
- TLN United States
- GMAB Denmark
- Employees
- TLN N/A
- GMAB N/A
- Industry
- TLN Electric Utilities: Central
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TLN Utilities
- GMAB Health Care
- Exchange
- TLN Nasdaq
- GMAB Nasdaq
- Market Cap
- TLN 18.6B
- GMAB 17.4B
- IPO Year
- TLN N/A
- GMAB N/A
- Fundamental
- Price
- TLN $364.46
- GMAB $30.47
- Analyst Decision
- TLN Strong Buy
- GMAB Strong Buy
- Analyst Count
- TLN 13
- GMAB 6
- Target Price
- TLN $415.38
- GMAB $40.40
- AVG Volume (30 Days)
- TLN 984.0K
- GMAB 2.2M
- Earning Date
- TLN 11-05-2025
- GMAB 11-06-2025
- Dividend Yield
- TLN N/A
- GMAB N/A
- EPS Growth
- TLN N/A
- GMAB 132.41
- EPS
- TLN 4.55
- GMAB 25.10
- Revenue
- TLN $2,343,000,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- TLN $13.60
- GMAB $24.92
- Revenue Next Year
- TLN $72.74
- GMAB $15.97
- P/E Ratio
- TLN $80.95
- GMAB $1.21
- Revenue Growth
- TLN 16.22
- GMAB 29.57
- 52 Week Low
- TLN $158.08
- GMAB $17.24
- 52 Week High
- TLN $451.28
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- TLN 40.56
- GMAB 57.23
- Support Level
- TLN $344.27
- GMAB $30.08
- Resistance Level
- TLN $398.44
- GMAB $30.78
- Average True Range (ATR)
- TLN 20.31
- GMAB 0.70
- MACD
- TLN -3.65
- GMAB 0.13
- Stochastic Oscillator
- TLN 28.60
- GMAB 84.70
About TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.